FDA approves once-monthly injection for opioid addiction

December 4, 2017

(HealthDay)—Sublocade, a once-monthly injection of buprenorphine to treat opioid use disorder, has been approved by the U.S. Food and Drug Administration.

Buprenorphine has been shown to reduce opioid withdrawal symptoms and the desire to use opioids, "without causing the cycle of highs and lows associated with or abuse," the FDA said.

Sublocade was evaluated in involving 848 adults who were diagnosed with moderate-to-severe cases of opioid use disorder. The most common side effects included constipation, nausea, vomiting, headache, drowsiness, and injection-site pain. Sublocade's safety and effectiveness were not evaluated in individuals under age 17, the FDA said.

The maker of Sublocade—Indivior—is required to conduct additional studies to see if some patients could benefit from a dose of Sublocade that's higher than currently approved.

Indivior is based in the United Kingdom.

Explore further: Clinical trial looks at tramadol for opioid withdrawal

More information: More Information

Related Stories

Clinical trial looks at tramadol for opioid withdrawal

July 12, 2017
A randomized clinical trial published by JAMA Psychiatry compared tramadol extended-release with clonidine and buprenorphine for the management of opioid withdrawal symptoms in patients with opioid use disorder in a residential ...

Injectable therapy blocks opioid euphoria, withdrawal symptoms in trial

June 26, 2017
A study led by investigators in the University of Kentucky Center on Drug and Alcohol Research (CDAR) has demonstrated a weekly injectable formulation of buprenorphine, CAM2038, suppresses symptoms of withdrawal in patients ...

Movantik approved for constipation from opioids

September 16, 2014
(HealthDay)—Movantik (naloxegol) has been approved by the U.S. Food and Drug Administration to treat opioid-induced constipation, the agency said Tuesday.

Gabapentin co-use may increase risk of fatal opioid overdose

October 3, 2017
Co-prescription of the anticonvulsant gabapentin is associated with an increased risk of opioid-related death in people who are prescribed opioid painkillers, according to a new study published in PLOS Medicine.

FDA asks maker of opioid painkiller opana ER to pull drug from market

June 9, 2017
(HealthDay)—Sales of reformulated Opana ER, a prescription opioid painkiller, should be halted in the United States, the U.S. Food and Drug Administration says.

Why are doctors underusing a drug to treat opioid addiction?

August 3, 2017
A drug approved for private physicians to treat opioid addiction is being underprescribed, and a survey of addiction specialists suggests that many of them are not willing to increase their use of it, despite an expanding ...

Recommended for you

Drug for spinal muscular atrophy prompts ethical dilemmas, bioethicists say

December 11, 2017
When the Food and Drug Administration approved the first drug for people with spinal muscular atrophy a year ago, clinicians finally had hope for improving the lives of patients with the rare debilitating muscular disease. ...

FDA's program to speed up drug approval shaved nearly a year off the process

December 7, 2017
Speeding the pace at which potentially lifesaving drugs are brought to market was a rallying cry for Donald Trump as a candidate, and is a stated priority of his Food and Drug Administration commissioner, Dr. Scott Gottlieb. ...

Dangers of commonly prescribed painkillers highlighted in study

December 6, 2017
Commonly prescribed painkillers need to be given for shorter periods of time to reduce the risk of obesity and sleep deprivation, a new study has revealed.

Viagra goes generic: Pfizer to launch own little white pill

December 6, 2017
The little blue pill that's helped millions of men in the bedroom is turning white. Drugmaker Pfizer is launching its own cheaper generic version of Viagra rather than lose most sales when the impotence pill gets its first ...

Surgery-related opioid doses can drop dramatically without affecting patients' pain

December 6, 2017
Some surgeons might be able to prescribe a third of opioid painkiller pills that they currently give patients, and not affect their level of post-surgery pain control, a new study suggests.

Four-fold jump in deaths in opioid-driven hospitalizations

December 4, 2017
People who end up in the hospital due to an opioid-related condition are four times more likely to die now than they were in 2000, according to research led by Harvard Medical School and published in the December issue of ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.